Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Evidence mapping based on systematic reviews of therapeutic interventions for soft tissue sarcomas.

Ballesteros M, Montero N, López-Pousa A, Urrútia G, Solà I, Rada G, Pardo-Hernandez H, Bonfill X.

Clin Transl Oncol. 2019 Mar 14. doi: 10.1007/s12094-019-02069-z. [Epub ahead of print]

PMID:
30875063
2.

The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial-like head and neck carcinoma subtypes.

Pavón MA, Arroyo-Solera I, León X, Téllez-Gabriel M, Virós D, Gallardo A, Céspedes MV, Casanova I, Lopez-Pousa A, Barnadas A, Quer M, Mangues R.

Head Neck. 2019 Jan 16. doi: 10.1002/hed.25623. [Epub ahead of print]

PMID:
30652380
3.

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.

Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J.

Lancet Oncol. 2019 Jan;20(1):134-144. doi: 10.1016/S1470-2045(18)30676-4. Epub 2018 Dec 18.

PMID:
30578023
4.

Effect of serpinE1 overexpression on the primary tumor and lymph node, and lung metastases in head and neck squamous cell carcinoma.

Arroyo-Solera I, Pavón MÁ, León X, López M, Gallardo A, Céspedes MV, Casanova I, Pallarès V, López-Pousa A, Mangues MA, Barnadas A, Quer M, Mangues R.

Head Neck. 2019 Feb;41(2):429-439. doi: 10.1002/hed.25437. Epub 2018 Dec 12.

PMID:
30548470
5.

Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).

Martin-Broto J, Hindi N, Cruz J, Martinez-Trufero J, Valverde C, De Sande LM, Sala A, Bellido L, De Juan A, Rubió-Casadevall J, Diaz-Beveridge R, Cubedo R, Tendero O, Salinas D, Gracia I, Ramos R, Baguè S, Gutierrez A, Duran-Moreno J, Lopez-Pousa A.

Oncologist. 2018 Nov 8. pii: theoncologist.2018-0121. doi: 10.1634/theoncologist.2018-0121. [Epub ahead of print]

PMID:
30409793
6.

Selective depletion of metastatic stem cells as therapy for human colorectal cancer.

Céspedes MV, Unzueta U, Aviñó A, Gallardo A, Álamo P, Sala R, Sánchez-Chardi A, Casanova I, Mangues MA, Lopez-Pousa A, Eritja R, Villaverde A, Vázquez E, Mangues R.

EMBO Mol Med. 2018 Oct;10(10). pii: e8772. doi: 10.15252/emmm.201708772.

7.

Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.

García Del Muro X, Maurel J, Martínez Trufero J, Lavernia J, López Pousa A, de Las Peñas R, Cubedo R, Berros JP, Casado Herráez A, de Juan A, Martín Broto J.

Invest New Drugs. 2018 Jun;36(3):468-475. doi: 10.1007/s10637-018-0583-z. Epub 2018 Mar 12.

PMID:
29527631
8.

High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial.

Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martin Broto J, Lopez-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Jurado JC, Comandone A, Grignani G, De Sanctis R, Palassini E, Llomboart-Bosch A, Dei Tos AP, Casali PG, Picci P, Gronchi A.

Eur J Cancer. 2018 Apr;93:28-36. doi: 10.1016/j.ejca.2018.01.071. Epub 2018 Feb 21.

PMID:
29475197
9.

Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.

Martin-Liberal J, López-Pousa A, Martínez-Trufero J, Martín-Broto J, Cubedo R, Lavernia J, Redondo A, López-Martín JA, Mulet-Margalef N, Sanjuan X, Tirado ÒM, Garcia-Del-Muro X.

Target Oncol. 2018 Feb;13(1):81-87. doi: 10.1007/s11523-017-0539-9.

PMID:
29177953
10.

SEOM clinical guideline in nasopharynx cancer (2017).

Pastor M, Lopez Pousa A, Del Barco E, Perez Segura P, Astorga BG, Castelo B, Bonfill T, Martinez Trufero J, Grau JJ, Mesia R.

Clin Transl Oncol. 2018 Jan;20(1):84-88. doi: 10.1007/s12094-017-1777-0. Epub 2017 Nov 2.

11.

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).

Martin-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, Garcia Del Muro X, Gutierrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martinez-Trufero J, Diaz-Beveridge R, Cruz J, Encinas V, Taron M, Moura DS, Luna P, Hindi N, Lopez-Pousa A.

Ann Oncol. 2017 Dec 1;28(12):2994-2999. doi: 10.1093/annonc/mdx536.

PMID:
29045512
12.

Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS).

Redondo A, Bagué S, Bernabeu D, Ortiz-Cruz E, Valverde C, Alvarez R, Martinez-Trufero J, Lopez-Martin JA, Correa R, Cruz J, Lopez-Pousa A, Santos A, García Del Muro X, Martin-Broto J.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1113-1131. doi: 10.1007/s00280-017-3436-0. Epub 2017 Oct 16.

13.

A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma.

Buonadonna A, Benson C, Casanova J, Kasper B, López Pousa A, Mazzeo F, Brodowicz T, Penel N.

Anticancer Drugs. 2017 Nov;28(10):1157-1165. doi: 10.1097/CAD.0000000000000560.

PMID:
28926423
14.

Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST).

Ballesteros M, Montero N, López-Pousa A, Urrútia G, Solà I, Rada G, Pardo-Hernandez H, Bonfill X.

BMC Med Res Methodol. 2017 Sep 7;17(1):135. doi: 10.1186/s12874-017-0402-9.

15.

GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).

Mora J, Castañeda A, Perez-Jaume S, Lopez-Pousa A, Maradiegue E, Valverde C, Martin-Broto J, Garcia Del Muro X, Cruz O, Cruz J, Martinez-Trufero J, Maurel J, Vaz MA, de Alava E, de Torres C.

Br J Cancer. 2017 Sep 5;117(6):767-774. doi: 10.1038/bjc.2017.252. Epub 2017 Aug 8.

16.

Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1).

Mañós M, Giralt J, Rueda A, Cabrera J, Martinez-Trufero J, Marruecos J, Lopez-Pousa A, Rodrigo JP, Castelo B, Martínez-Galán J, Arias F, Chaves M, Herranz JJ, Arrazubi V, Baste N, Castro A, Mesía R.

Oral Oncol. 2017 Jul;70:58-64. doi: 10.1016/j.oraloncology.2017.04.004. Epub 2017 Apr 17. Review.

17.

KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer.

Sullivan I, Salazar J, Arqueros C, Andrés M, Sebio A, Majem M, Szafranska J, Martínez E, Páez D, López-Pousa A, Baiget M, Barnadas A.

Clin Transl Oncol. 2017 Jul;19(7):884-890. doi: 10.1007/s12094-017-1620-7. Epub 2017 Feb 1.

PMID:
28150169
18.

SEOM Clinical Guideline of management of soft-tissue sarcoma (2016).

López-Pousa A, Martin Broto J, Martinez Trufero J, Sevilla I, Valverde C, Alvarez R, Carrasco Alvarez JA, Cruz Jurado J, Hindi N, Garcia Del Muro X.

Clin Transl Oncol. 2016 Dec;18(12):1213-1220. doi: 10.1007/s12094-016-1574-1.

19.

Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.

Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Jurado JC, De Paoli A, Donati DM, Poveda A, Quagliuolo V, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG, Picci P.

Ann Oncol. 2016 Dec;27(12):2283-2288. doi: 10.1093/annonc/mdw430. Epub 2016 Oct 11.

PMID:
27733375
20.

Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study.

Maurel J, López-Pousa A, Calabuig S, Bagué S, Del Muro XG, Sanjuan X, Rubió-Casadevall J, Cuatrecasas M, Martinez-Trufero J, Horndler C, Fra J, Valverde C, Redondo A, Poveda A, Sevilla I, Lainez N, Rubini M, García-Albéniz X, Martín-Broto J, de Alava E.

Clin Sarcoma Res. 2016 Jun 29;6:10. doi: 10.1186/s13569-016-0050-6. eCollection 2016.

21.

Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.

Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I, Pavón MA, Mangues MA, Trías M, López-Pousa A, Villaverde A, Vázquez E, Mangues R.

Nanomedicine. 2016 Oct;12(7):1987-1996. doi: 10.1016/j.nano.2016.04.003. Epub 2016 Apr 13.

PMID:
27085904
22.

CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carcinoma.

Pavón MA, Parreño M, Téllez-Gabriel M, León X, Arroyo-Solera I, López M, Céspedes MV, Casanova I, Gallardo A, López-Pousa A, Mangues MA, Quer M, Barnadas A, Mangues R.

Head Neck. 2016 Apr;38 Suppl 1:E1392-403. doi: 10.1002/hed.24232. Epub 2015 Oct 30.

PMID:
26516695
23.

Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.

Pavón MA, Arroyo-Solera I, Téllez-Gabriel M, León X, Virós D, López M, Gallardo A, Céspedes MV, Casanova I, López-Pousa A, Mangues MA, Quer M, Barnadas A, Mangues R.

Oncotarget. 2015 Oct 6;6(30):29016-33. doi: 10.18632/oncotarget.5032.

24.

Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide.

Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, Comandone A, Sangalli C, Palmerini E, Lopez-Pousa A, De Sanctis R, Bottelli S, Libertini M, Picci P, Casali PG, Gronchi A.

J Clin Oncol. 2015 Nov 1;33(31):3628-34. doi: 10.1200/JCO.2015.62.9394. Epub 2015 Sep 8.

PMID:
26351345
25.

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

Blay JY, Pápai Z, Tolcher AW, Italiano A, Cupissol D, López-Pousa A, Chawla SP, Bompas E, Babovic N, Penel N, Isambert N, Staddon AP, Saâda-Bouzid E, Santoro A, Franke FA, Cohen P, Le-Guennec S, Demetri GD.

Lancet Oncol. 2015 May;16(5):531-40. doi: 10.1016/S1470-2045(15)70102-6. Epub 2015 Apr 8.

PMID:
25864104
26.

Giant cell tumour of bone: new treatments in development.

López-Pousa A, Martín Broto J, Garrido T, Vázquez J.

Clin Transl Oncol. 2015 Jun;17(6):419-30. doi: 10.1007/s12094-014-1268-5. Epub 2015 Jan 24. Review.

27.

Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).

Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, Del Muro JG, Fra J, Redondo A, Lainez N, Poveda A, Valverde C, De Juan A, Sevilla I, Casado A, Andres R, Cruz J, Martin-Broto J, Maurel J; Spanish Group for Research on Sarcoma (GEIS).

Ann Surg Oncol. 2015 Sep;22(9):2948-57. doi: 10.1245/s10434-014-4360-8. Epub 2015 Jan 22.

PMID:
25608769
28.

Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.

León X, Agüero A, López M, García J, Farré N, López-Pousa A, Quer M.

Auris Nasus Larynx. 2015 Apr;42(2):145-9. doi: 10.1016/j.anl.2014.10.002. Epub 2014 Nov 13.

PMID:
25459494
29.

Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.

Alamo P, Gallardo A, Di Nicolantonio F, Pavón MA, Casanova I, Trias M, Mangues MA, Lopez-Pousa A, Villaverde A, Vázquez E, Bardelli A, Céspedes MV, Mangues R.

FASEB J. 2015 Feb;29(2):464-76. doi: 10.1096/fj.14-262303. Epub 2014 Oct 30.

30.

Differences between en bloc resection and enucleation of retroperitoneal sarcomas.

Gonzalez Lopez JA, Artigas Raventós V, Rodríguez Blanco M, Lopez-Pousa A, Bagué S, Abellán M, Trias Folch M.

Cir Esp. 2014 Oct;92(8):525-31. doi: 10.1016/j.ciresp.2014.02.002. Epub 2014 Apr 13. English, Spanish.

PMID:
24726340
31.

High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.

Téllez-Gabriel M, Arroyo-Solera I, León X, Gallardo A, López M, Céspedes MV, Casanova I, López-Pousa A, Quer M, Mangues MA, Barnadas A, Mangues R, Pavón MA.

Cancer Med. 2013 Dec;2(6):950-63. doi: 10.1002/cam4.153. Epub 2013 Oct 31.

32.

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernández JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).

Ann Oncol. 2014 Jan;25(1):216-25. doi: 10.1093/annonc/mdt461. Epub 2013 Nov 19.

PMID:
24256848
33.

MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.

Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, Casali PG, Fernandez-Serra A, Lopez-Pousa A, Gronchi A.

Mol Cancer Ther. 2014 Jan;13(1):249-59. doi: 10.1158/1535-7163.MCT-13-0406. Epub 2013 Oct 21.

34.

SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013.

Redondo A, Cruz J, Lopez-Pousa A, Barón F; SEOM.

Clin Transl Oncol. 2013 Dec;15(12):1037-43. doi: 10.1007/s12094-013-1087-0. Epub 2013 Aug 2.

PMID:
23907290
35.

Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.

Martín-Liberal J, López-Pousa A, Broto JM, Cubedo R, Gallego O, Brendel E, Tirado OM, del Muro XG.

Invest New Drugs. 2014 Apr;32(2):287-94. doi: 10.1007/s10637-013-9989-9. Epub 2013 Jun 26.

PMID:
23801301
36.

[Primary, non-metastatic gastrointestinal stromal tumour surgery: results of the GRISK study].

Artigas Raventós V, López Pousa A, Ortega Medina L, Díaz de Liaño Argüelles A, Fernández Hernández JÁ, Lucena de la Poza JL.

Cir Esp. 2013 Feb;91(2):96-102. doi: 10.1016/j.ciresp.2012.05.002. Epub 2012 Jun 28. Spanish.

PMID:
22748847
37.

Gene expression signatures and molecular markers associated with clinical outcome in locally advanced head and neck carcinoma.

Pavón MA, Parreño M, Téllez-Gabriel M, Sancho FJ, López M, Céspedes MV, Casanova I, Lopez-Pousa A, Mangues MA, Quer M, Barnadas A, León X, Mangues R.

Carcinogenesis. 2012 Sep;33(9):1707-16. doi: 10.1093/carcin/bgs207. Epub 2012 Jun 13.

PMID:
22696598
38.

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.

Ryan CW, Matias C, Agulnik M, Lopez-Pousa A, Williams C, de Alwis DP, Kaiser C, Miller MA, Ermisch S, Ilaria R Jr, Keohan ML.

Invest New Drugs. 2013 Feb;31(1):145-51. doi: 10.1007/s10637-012-9819-5. Epub 2012 Apr 27.

PMID:
22539091
39.

Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.

Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG, Picci P.

J Clin Oncol. 2012 Mar 10;30(8):850-6. doi: 10.1200/JCO.2011.37.7218. Epub 2012 Feb 6.

PMID:
22312103
40.

[Head and neck sarcomas. Our experience].

Piñeiro Aguín Z, León Vintró X, García Lorenzo J, Sancho FJ, López Pousa A, Quer Agustí M.

Acta Otorrinolaringol Esp. 2011 Nov-Dec;62(6):436-42. doi: 10.1016/j.otorri.2011.05.005. Epub 2011 Aug 5. Spanish.

41.

Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

García-Del-Muro X, López-Pousa A, Maurel J, Martín J, Martínez-Trufero J, Casado A, Gómez-España A, Fra J, Cruz J, Poveda A, Meana A, Pericay C, Cubedo R, Rubió J, De Juan A, Laínez N, Carrasco JA, de Andrés R, Buesa JM; Spanish Group for Research on Sarcomas.

J Clin Oncol. 2011 Jun 20;29(18):2528-33. doi: 10.1200/JCO.2010.33.6107. Epub 2011 May 23.

PMID:
21606430
42.

Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study).

Barnadas A, Mesía R, Majem M, Galiana R, López-Pousa A, de Vega JM, Margelí M, Valentí V, Anglada L, Lloansí A, Arellano A.

Clin Transl Oncol. 2011 Apr;13(4):254-60. doi: 10.1007/s12094-011-0650-9.

PMID:
21493186
43.

Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.

Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martínez-Trufero J, López-Pousa A, Del Muro XG, Lomeña F, Maurel J, Pons F.

Q J Nucl Med Mol Imaging. 2011 Dec;55(6):680-7. Epub 2010 Dec 9.

PMID:
21150863
44.

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

Paz-Ares L, López-Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, del Muro JG, Provencio M, Casado A, Rivera-Herrero F, Izquierdo MA, Nieto A, Tanović A, Cortes-Funes H, Buesa JM.

Invest New Drugs. 2012 Apr;30(2):729-40. doi: 10.1007/s10637-010-9561-9. Epub 2010 Oct 20.

PMID:
20960029
45.

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.

Maurel J, Martins AS, Poveda A, López-Guerrero JA, Cubedo R, Casado A, Martínez-Trufero J, Ramón Ayuso J, Lopez-Pousa A, Garcia-Albeniz X, Garcia del Muro X, de Alava E.

Cancer. 2010 Aug 1;116(15):3692-701. doi: 10.1002/cncr.25111.

46.

Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours.

López-Pousa A, Rifà J, Casas de Tejerina A, González-Larriba JL, Iglesias C, Gasquet JA, Carrato A; DELFOS Study Group.

Eur J Cancer Care (Engl). 2010 Sep;19(5):648-55. doi: 10.1111/j.1365-2354.2009.01121.x. Epub 2010 Jan 19.

47.

Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.

Aapro M, Schwenkglenks M, Lyman GH, Lopez Pousa A, Lawrinson S, Skacel T, Bacon P, von Minckwitz G.

Crit Rev Oncol Hematol. 2010 Jun;74(3):203-10. doi: 10.1016/j.critrevonc.2009.06.004. Epub 2009 Sep 11. Review.

48.

[Clinical practice guidelines in gastrointestinal stromal tumours (GEIS): update 2008].

Poveda A, Artigas V, Casado A, Cervera J, García Del Muro X, Antonio López-Guerrero J, López-Pousa A, Maurel J, Ortega L, Ramos R, Romero I, Safont MJ, Martín J; Grupo Español de Investigación en Sarcomas (GEIS).

Cir Esp. 2008 Oct;84 Suppl 1:1-21. Spanish. No abstract available.

49.

Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.

Maurel J, López-Pousa A, de Las Peñas R, Fra J, Martín J, Cruz J, Casado A, Poveda A, Martínez-Trufero J, Balañá C, Gómez MA, Cubedo R, Gallego O, Rubio-Viqueira B, Rubió J, Andrés R, Sevilla I, de la Cruz JJ, Del Muro XG, Buesa JM.

J Clin Oncol. 2009 Apr 10;27(11):1893-8. doi: 10.1200/JCO.2008.19.2930. Epub 2009 Mar 9.

PMID:
19273704
50.

Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer.

Pavón MA, Parreño M, León X, Sancho FJ, Céspedes MV, Casanova I, Lopez-Pousa A, Mangues MA, Quer M, Barnadas A, Mangues R.

Int J Cancer. 2008 Sep 1;123(5):1068-79. doi: 10.1002/ijc.23635.

Supplemental Content

Loading ...
Support Center